Immediate Impact
1 by Nobel laureates 3 from Science/Nature 54 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Danielle Jandial being referenced
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
2022
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Danielle Jandial | 309 | 175 | 219 | 204 | 20 | 857 | |
| Silvia Rossi | 337 | 98 | 150 | 461 | 59 | 1.1k | |
| Mary Morgan | 193 | 162 | 102 | 324 | 32 | 1.0k | |
| Xiang Yin | 399 | 146 | 36 | 64 | 13 | 916 | |
| Dillwyn Williams | 214 | 159 | 21 | 64 | 27 | 1.1k | |
| Ming-Chih Chou | 177 | 353 | 28 | 143 | 37 | 1.0k | |
| Wenjing Tian | 146 | 258 | 189 | 107 | 59 | 1.0k | |
| Melissa M. Moore | 524 | 229 | 37 | 162 | 51 | 1.1k | |
| Jocelyn M. Weiss | 126 | 371 | 27 | 150 | 24 | 1.0k | |
| Emma De Feo | 159 | 341 | 64 | 59 | 24 | 944 | |
| Nalini Chandar | 250 | 406 | 117 | 56 | 43 | 805 |
All Works
Loading papers...